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This study aims to assess the association of two single nucleotide polymorphisms (SNPs), G34A and C376T, in the 
ABCG2 gene with the risk of developing CRC. To the best of our knowledge, this is the first study that determined the role 
of genetic variations in the ABCG2 gene with the risk of CRC in Saudi Arabia. The gDNA was extracted from the blood of 
58 CRC patients and 48 healthy subjects. The DNA sequencing was used to determine the distribution of genotypes. The 
results showed that CRC patients carried a heterozygous (GA) genotype for SNP G34A had a low risk of developing CRC 
(odds ratio=0.015, 95% CI [0.00–0.12]; risk ratio=0.35, 95% CI [0.25–0.12], P <0.0001). On the other hand, patients that 
carried a heterozygous (CT) genotype for SNP C376T had a high risk of developing CRC (odds ratio=13.83, 95% CI  
[4.31–44.38]; risk ratio=4.88, 95% CI [1.95–12.24], P <0.0001). In conclusion, the results indicated that a heterozygous 
(GA) genotype in SNP G34A may decrease the risk of CRC development, whereas, the heterozygous (CT) genotype in SNP 
C376T may increase the risk of CRC. The results may suggest a protective role of ABCG2 SNP G34A against CRC and a 
deleterious effect of ABCG2 SNP C376T for increasing the risk of CRC. 
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Nearly one to two million new cases of colorectal 
cancer (CRC) are diagnosed every year. This high 
incidence rate makes CRC the third most common 
type of cancer and the fourth most common cause of 
cancer-related deaths in the world. By gender, CRC 
represents the second most common tumor in women 
(9.2%) and the third most common tumor in men 
(10%)
1,2
. In the Kingdom of Saudi Arabia (KSA), 
CRC represents the first and third most common 
malignancy in men and women, respectively
3
. CRC 
survival is highly dependent on the stage of the 
disease at diagnosis. In general, diagnosis at an early 
stage gives a high greater chance of survival, and the 
five-year survival rate is 95%, 82%, 61%, and 8% for 
CRC patients in stages I, II, III, and IV, respectively
4,5
.  
There are several etiologic factors that are linked 
with the incidence of CRC, such as age, lifestyle, and 
genetic mutations
4
. Colorectal carcinomas are 
classified as sporadic, inherited, or familial carcinoma, 
according to the source of the mutation. More than 
70% of all diagnosed CRC cases are sporadic
2,6
. One of 
the major gene families that contribute to cancer 
development or treatment response is the ATP-binding 
cassette (ABC) transporter family, and the breast 
cancer resistance protein (BCRP/ABCG2) is a member 
of the ABC transporter super family.  
The ABCG2 gene is located on chromosome 4q22, 
spans more than 66 kb, and consists of 16 exons 
ranging from 60 to 532 base pairs
7
. It is prominently 
expressed in the placenta, colonic epithelium, small 
intestine, liver, lungs, and kidneys
8-10
. The expression 
and activity of the human ABCG2 protein differ 
between individuals due to genetic polymorphisms, 
and the analysis and validation of single nucleotide 
polymorphisms (SNPs) occurring in the ABCG2 gene 
are of clinical importance
10
. The two most frequently 
occurring SNPs, G34A in exon 2 and C376T in  
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exon 4, were found to alter the transporter function, 
alter sensitivity to several anticancer drugs, and 
disrupt protein expression. Therefore, they may affect 
the response of cancer cells to therapy and result in 
increased susceptibility to different types of cancers
11
. 
Studies have revealed that carriers with the minor 
allele (A) of both SNP G34A and SNP C421A in the 
ABCG2 gene had a significantly increased risk of 
breast carcinoma
12
 and diffuse large B-cell lymphoma 
(DLBCL)
13
. Furthermore, one study indicated that 
heterozygous carriers of the G alleles of rs2622621 
and rs1481012 in the ABCG2 gene had a decreased 
risk of CRC
10
. A combination of SNPs C376T  
and C421A would have a negative effect on 
ABCG2/BCRP activity, and the combined variant is 
expected to show reduced ABCG2/BCRP activity
14
.
 
Based on the previous background, SNPs in  
the gene encoding ABCG2 were found to alter  
the functional significance of the transporter. 
Therefore, the present study aimed to illustrate  
the effect of two SNPs (G34A and C376T) in the 
ABCG2 transporter gene on the prognosis for CRC in 
Saudi patients. 
 
Materials and Methods 
 
Subjects and samples 
This case-controlled study was conducted on 106 
volunteers. The study comprised of 48 healthy control 
subjects and 58 CRC patients. The whole blood of the 
control samples was collected from King Fahad 
General Hospital (KFGH) – blood bank unit in Jeddah, 
KSA, while the blood samples of the CRC patients 
were collected from oncology centers at King 
Abdulaziz University (KAU) Hospital and King 
Abdullah Medical City (KAMC) in Jeddah, KSA. All 
study subjects agreed to participate in this study, signed 
informed consent, and answered a questionnaire  
that included information about their physical 
characteristics and medications they were taking. The 
study was approved by the Unit of Biomedical Ethics 
at the Faculty of Medicine (reference no. 261-15), 
KAU, Jeddah, KSA. DNA was extracted from the 
whole blood samples of patients and healthy controls 
using the QIAamp DNA Blood Mini Kit (catalog no. 
51306; QIAGEN, Germantown, MD, USA). 
 
Amplification of SNPs (G34A and C376T) in the ABCG2 gene 
To prepare a 25 µL PCR reaction, 1 µL genomic 
DNA (100 pmol/µL), 12.5 µL HotStarTaqMaster Mix 
(catalog no. 71156; Affymetrix, Santa Clara, CA, 
USA), 9.5 µL RNase free water (catalog no. 71156; 
Affymetrix, Santa Clara, CA, USA), and 1 µL of each 
primer were used. The PCR thermocycler conditions 
for both SNPs are shown in (Table 1). 
 
Genotyping of SNPs (G34A and C376T) in the ABCG2 gene 
The different genotypes of SNPs G34A and C376T 
were determined with a DNA sequencing technique. 
The sequencing was done at the Centre of Excellence 
in Genomic Medicine Research (CEGMR) at King 
Fahd Medical Research Center (KFMRC), KAU, 
Jeddah, Saudi Arabia. 
 
Statistical analysis 
All statistical analyses were performed using 
GraphPad Prism version 5.0 (GraphPad Software, San 
Diego, CA, USA). The unpaired t-test was used to 
compare one variable between the two groups. Using 
a 2 × 2 contingency table, the chi-square (χ2) test was 
used to determine the allele frequency, genotype 
distribution, odds ratio (OR), risk ratio (RR), and 
Fisher’s exact P values according to the Hardy–
Weinberg equilibrium assumption. All P values <0.05 
were considered statistically significant. 
 
Results 
 
Comparison of the physical characteristics between patients 
and controls 
As shown in (Table 2), the results indicated that 
there were significant differences between the patients 
and the controls about weight (P=0.003) and body 
mass index (BMI) (P=0.003). The differences in 
weight and BMI are due to the loss of appetite in 
patients because of chemotherapy. 
 
Genotypes and allele frequencies of ABCG2 SNP G34A in 
patients and controls 
The genotype frequencies of the patients were 40% 
(n=23) normal (GG), 59% (n=34) heterozygous (GA), 
Table 1 — PCR primers and cycling conditions for ABCG2 SNPs amplification 
Locus Primers (5-3) Cycling conditions 
Exon 2 
SNP G34A 
For: CAGTAATGTCGAAGTTTTTATCGCA 
Rev: AAATGTTCATAGCCAGTTCTTGGA 
95C/1 min, followed by 25 cycles of 95C/30 sec, 
60C/30 sec, and 68C/1 min.  
Final extension at 68C/5 min Exon 4 
SNP C376T 
For: TAGGGAAAGGAAGCAGAAGATGTAAGTAAA 
Rev: TAAGCTAGGGGAAAAGAAAGGTGAAGGA 
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and 2% (n=1) homozygous (AA), and the frequency 
of the G and A alleles were 70% and 30%, 
respectively. The genotype distribution of CRC 
patients was out of Hardy–Weinberg equilibrium 
(χ2=4.84, degree of freedom [DF]=1, 0.05<P <0.025). 
The genotype frequencies of controls were 92% 
(n=44) normal (GG), 2% (n=1) heterozygous (GA), 
and 6% (n=3) homozygous (AA), and the allele 
frequencies for G and A were 93% and 7%, 
respectively. The genotype distribution of controls 
was out of Hardy–Weinberg equilibrium (χ2=36.31, 
DF=1, P <0.05). In comparing the results for the 
patients and the controls, shown in (Table 3), the 
occurrence of the normal (GG) to heterozygous (GA) 
genotype was significantly different (P <0.0001); 
however, the calculated OR and RR were not high. 
The results indicate that SNP G34A protects against 
CRC development. 
 
Genotypes and allele frequencies of ABCG2 SNP G34A in 
male and female patients 
The genotype frequencies of G34A in male  
patients were 41.30% (n=19) normal (GG), 58.70% 
(n=27) heterozygous (GA), and 0% (n=0) 
homozygous (AA), and the G and A allele frequencies 
were 70.65% and 29.35%, respectively. The  
genotype distribution of CRC male patients was  
out of Hardy–Weinberg equilibrium (χ2=7.93,  
DF=1, 0.005<P <0.002). In female CRC patients,  
the results showed 33.33% (n=4) normal (GG), 
58.33% (n=7) heterozygous (GA), and 8.33%  
(n=1) homozygous (AA) genotypes, and the G and  
A allele frequencies were 29.17% and 70.83%, 
respectively. The genotype distribution was out of 
Hardy–Weinberg equilibrium (χ2=13.72, DF=1, 
P<0.05). Although the frequency of genotypes  
was out of Hardy–Weinberg equilibrium in both  
male and female CRC patients, none of them  
showed a significant difference in an increased risk of 
CRC development. 
 
Genotypes and allele frequencies of ABCG2 SNP G34A in 
male and female controls 
The genotype frequencies of male controls were 
95.75% (n=30) normal (GG), 3.13% (n=1) 
heterozygous (GA), and 3.13% (n=1) homozygous 
(AA), and the G and A allele frequencies were 
95.32% and 4.68%, respectively. The genotype 
distribution was out of Hardy–Weinberg equilibrium 
(χ2=13.58, DF=1, P <0.05). In female controls, the 
results showed 87.50% (n=14) normal (GG), 0% 
(n=0) heterozygous (GA), and 12.5% (n=2) 
homozygous (AA) genotypes, and the G and A allele 
frequencies were 87.50% and 12.50%, respectively. 
The genotype distribution of female controls 
regarding SNP G34A was out of Hardy–Weinberg 
equilibrium (χ2=16, DF=1, P <0.05). The results 
indicate a protective role of SNP G34A in the ABCG2 
gene against the development of CRC. 
Table 3 — Genotypes and allele frequencies of the ABCG2 gene SNPs G34A and C376T for patients and controls 
SNP G34A 
 Patients, n (%) Controls, n (%) P value Odds ratio (95% CI) Risk ratio (95% CI) 
GG 23 (40) 44 (92)  1.0 (Reference) 1.0 (Reference) 
GA 34 (59) 1 (2) <0.0001 0.02 (0.002-0.12) 0.35 (0.25-0.50) 
AA 1 (2) 3 (6) 1 1.57 (0.15-15.94) 1.37 (0.24-7.74) 
G 40 (70) 44 (93)  1.0 (Reference) 1.0 (Reference) 
A 18 (30) 4 (7) <0.0001 0.18 (0.07-0.42) 0.53 (0.42-0.67) 
SNP C376T 
 Patients, n (%) Controls, n (%) P value Odds ratio (95%CI) Risk ratio (95% CI) 
CC 53 (91.38) 23 (47.92)  1.00 (Reference) 1.0 (Reference) 
CT 4 (6.90) 24 (50) <0.0001 13.83 (4.31-44.38) 4.88 (1.95-12.24) 
TT 1 (1.72) 1 (2.1) 1 2.30 (0.14-38.46) 1.39 (0.35-5.62) 
C 55 (94.83) 35 (72.92)  1.0 (Reference) 1.0 (Reference) 
T 3 (5.17) 13 (27.1) <0.0001 7.03 (2.58-19.14) 3.62 (1.60-8.18) 
 
Table 2 — Mean values and standard errors of physical 
characteristics comparison between patients and controls 
Physical 
characteristics 
Patients 
(n=58) 
Controls  
(n=48) 
Unpaired t-test 
P value 
Age (years) 56.14 ±1.70 52.54 ± 1.90 0.15 
Height (cm) 165.50 ± 1.24 166.30 ± 1.44 0.67 
Weight (kg) 73.33 ± 2.06 84.13 ± 3.00 0.003 
Waist (cm) 100.60± 2.70 99.85 ± 2.29 0.84 
Hip (cm) 110.0 ± 2.55 109.90 ± 2.41 0.98 
Waist to hip ratio 
(WHR) 
0.921 ± 0.02 0.915 ± 0.02 0.82 
Body mass index 
(BMI) (kg/m2) 
26.82 ± 0.75 30.54 ±0.97 0.003 
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Genotypes and allele frequencies of ABCG2 SNP C376T for 
patients and controls 
The genotype frequencies of patients were 91.38% 
(n=53) normal (CC), 6.9% (n=4) heterozygous (CT), 
and 1.72% (n=1) homozygous (TT), and the 
frequency of the C and T alleles were 94.83% and 
5.17%, respectively. The genotype distribution of 
CRC patients was out of Hardy–Weinberg 
equilibrium (χ2=5.13, DF=1, 0.025<P <0.02). In 
controls, the results showed 47.92% (n=23) normal 
(CC), 50% (n=24) heterozygous (CT), and 2.1% 
(n=1) homozygous (TT), and the allele frequencies 
for C and T were 72.92% and 27.10%, respectively. 
The genotype distribution of controls was out of 
Hardy–Weinberg equilibrium (χ2=23.14, DF=1,  
P <0.05).  
In comparing the results for the patients and 
controls, shown in (Table 3), surprisingly, the 
occurrence of the normal (CC) to heterozygous (CT) 
genotype was significant and greatly different  
(P <0.0001), which is compatible with the calculated 
OR (13.83) and RR (4.88). Moreover, when the 
occurrence of the normal (CC) to homozygous (TT) 
genotype was calculated, the RR was equal in the two 
groups, which indicates a similarity in the ratio of the 
probability of exposure and outcome in the patient 
and control groups. However, the OR was slightly 
increased (OR=2.3), but since the P- value (Fisher’s 
exact probability test) was not significant (P=1) due 
to small sample size, we cannot confirm the role of 
the homozygous (TT) genotype in increasing the risk 
of CRC development. To confirm our findings, the 
allele frequencies were also compared. The results 
from a chi-square analysis showed that most of the 
patients and controls carried the major allele (C) as 
compared to the number of patients and controls that 
carried the minor allele (T). However, the OR and RR 
were extremely high (OR=7.03, 95%CI [2.58-19.14], 
and RR=3.62, 95% CI [1.60-8.18]), with a significant 
high P value (<0.0001). These results confirm that 
subjects with the minor allele (T), whether 
heterozygous (CT) or homozygous (TT), are at a 
greater risk of developing CRC compared to the 
subjects carrying the major allele (C) in the form of a 
normal genotype (CC). 
 
Genotypes and allele frequencies of ABCG2 SNP C376T for 
male and female patients 
The genotype frequencies of the C376T variant in 
male patients showed 93.48% (n=43) normal (CC), 
4.35% (n=2) heterozygous (CT), and 2.17% (n=1) 
homozygous (TT), and the C and T allele frequencies 
were 95.66% and 4.34%, respectively. The genotype 
distribution of male patients was out of Hardy–
Weinberg equilibrium (χ2=10.47, DF=1, 0.002  
<P <0.001). In females, the results showed 83.33% 
(n=10) normal (CC), 16.67% (n=2) heterozygous 
(CT), and 0% (n=0) homozygous (TT) genotypes, and 
the C and T allele frequencies were 91.67% and 
8.33%, respectively. The genotype distribution of 
female patients was within Hardy–Weinberg 
equilibrium (χ2=0.10, DF=1, 0.98<P <0.20). Results 
from a chi-square analysis showed that there was no 
significant difference in genotype distribution and the 
risk of developing CRC regarding to gender. 
 
Genotypes and allele frequencies of ABCG2 SNP C376T for 
male and female controls 
The genotype frequencies of the C376T variant in 
male controls showed 50% (n=16) normal (CC), 
46.88% (n=15) heterozygous (CT), and 3.13% (n=1) 
homozygous (TT), and the C and T allele frequencies 
were 73.44% and 26.56%, respectively. The genotype 
distribution of male controls was within Hardy–
Weinberg equilibrium (χ2=1.30, DF=1, 0.98< 
P <0.20). In females, the results showed 43.75% 
(n=7) normal (CC), 56.25% (n=9) heterozygous (CT), 
and 0% (n=0) homozygous (TT) genotypes, and the C 
and T allele frequencies were 71.88% and 28.12%, 
respectively. The genotype distribution of female 
controls was within Hardy–Weinberg equilibrium 
(χ2=2.45, DF=1, 0.20<P <0.10). Results from a  
chi-square analysis showed that there was no 
significant difference in genotype distribution and the 
risk of developing CRC in relation to gender. 
 
Discussion  
CRC is one of the most commonly diagnosed 
cancers worldwide. In 2015, CRC ranked as the third 
most common cancer in males and the second most 
common type in females, giving rise to an estimated 
753000 deaths worldwide
15,16
. In Saudi Arabia, CRC 
represents the first most common cancer in males and 
the third in females
3
. One of the studied mechanisms 
that explain drug resistance and increases the risk of 
developing cancer is the expression of ABCG2, a drug 
efflux pump and a member of the ABC drug 
transporter family
17
. ABCG2 is widely expressed on 
the surfaces of many tissues, including epithelial cells 
in the colon
8,10,18
. SNPs in the ABCG2 gene have been 
found to change the expression and activity of the 
corresponding gene and its product. Therefore, it may 
increase the susceptibility to different types of 
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cancers
7,19
. The ABCG2 SNPs, G34A, which resulted 
in a V12M change in exon 2, and C376T (substituting 
stop codon for Gln-126) in exon 4, are two of the 
most studied SNPs
13,20
. The ABCG2 SNP G34A is 
related to disturbed transporter membrane localization 
of ABCG2 and drug efflux
21,22
. Moreover, SNP 
C376T has been found to affect protein expression 
due to the premature stop codon
20
. For this reason, 
experiments are currently perform to overcome this 
obstacle by studying the response of CRC patients 
towards many chemotherapeutic agents such as  
5-fluorouracil (5-FU) and thymidine phosphorylase 
inhibitors
 
as well as to identify new biomarkers to 
assess drug response in cancer
23-25
. 
Several studies have related ABCG2 SNPs with the 
risk of different types of diseases, most notably 
cancers. Wu and his team found that carriers with the 
ABCG2 G34A A allele and the C421A A allele and 
haplotype G34A A-C421A C or G34A G-C421A A 
had a significantly increased risk of breast 
carcinoma
12
. The variants 421C>A and 34G>A were 
associated with an increased risk of DLBCL
12,13
. 
Furthermore, a study published by Campa et al.
10
 
indicated that heterozygous carriers of the G alleles of 
rs2622621 and rs1481012 in the ABCG2 gene had a 
decreased risk of CRC. However, more studies 
regarding ABCG2 SNPs have focused on drug 
resistance because this transporter contributes greatly 
to treatment response. 
In the current study, we were concerned about the 
contribution of allele frequencies and genotype 
distributions of two SNPs (G34A and C376T) in the 
ABCG2 transporter gene to an increased risk of CRC 
(as it is among the most common types of cancer in 
males and females in the KSA). Interestingly, for the 
first time in the KSA, to the best of our knowledge, 
we found that CRC subjects carrying the 
heterozygous (GA) genotype of the G34A variant 
showed a low risk of CRC, as determined by their 
calculated OR, whereas, patients with the 
homozygous (AA) genotype had a slightly higher 
degree of risk compared to heterozygous (GA) 
subjects, although the Pvalue was not significant due 
to the small sample size used in the comparison. This 
result might suggest a protective role of the 
heterozygous (GA) genotype of ABCG2 SNP G34A 
against CRC development. Our results disagree with 
another study, which was done on breast cancer 
patients that found the G34A GA/AA genotypes were 
significantly associated with an increased risk of 
breast cancer
12
. A recent study performed on Polish 
myeloma patients found that SNP C421A in ABCG2 
gene may be used as a predictor for multiple 
myeloma, whereas, SNP G34A was expressed 
normally in the study population and therefore, cannot 
be used as a predictor marker for myeloma
26
. 
Concerning the C376T variant in this study, the 
results for the patients and controls with the 
heterozygous (CT) genotype indicated a high risk of 
CRC. Our results indicate that the heterozygous 
genotype (CT) of the C376T variant increased the risk 
of CRC development more than the normal genotype 
(CC). Interestingly, there have been less studies done 
to indicate the correlation of SNP C376T with a risk 
of cancer, however, a recent study was performed on 
580 advanced CRC patients to assess the role of 
polymorphisms in DNA repair genes and ABCG2 
gene. They have found that the XPA DNA repair gene 
and ABCG2 gene had significant interaction with 
environmental factors and prognosis of CRC, 
especially in CRC patients receiving oxaliplatin-based 
chemotherapy
27
. 
 
Conclusion 
The results of this study suggest a protective role of 
the heterozygous (GA) genotype in SNP G34A 
against CRC development. Our data also suggest an 
increased risk of developing CRC in subjects with the 
heterozygous (CT) genotype in SNP C376T. 
However, this study had some limitations. These 
results need to be investigated with a larger number of 
patients, and an in vitro study on patients’ tissues 
should be performed to determine the expression of 
the transporter using an immunohistochemistry 
technique. 
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